View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2015	May 15, 2015
Document And Entity Information
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,638,811
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Balance Sheets - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$ 1,453,505	$ 141,944
Prepaid expenses and deposits	82,504	82,504
Total Assets	1,536,009	224,448
Current Liabilities
Accounts payable and accrued liabilities	703,323	693,362
Research agreement obligations	492,365	492,365
Derivative liability – warrants	2,052,975	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	3,301,605	1,248,084
Stockholders’ Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)	32,639	20,319
Additional paid-in capital	85,493,220	85,265,776
Deficit accumulated during the development stage	(87,291,455)	(86,309,731)
Total Stockholders’ Deficit	(1,765,596)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,536,009	224,448
Series A
Stockholders’ Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B
Stockholders’ Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000
Common stock shares issued	32,638,811	20,318,815
Common stock shares outstanding	32,638,811	20,318,815
Convertible preferred stock	10,000,000	10,000,000
Preferred stock par value	$ 0.001
Series A
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

Statements of Operations - USD ($)	3 Months Ended
Statements of Operations - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
General and administrative	$ 418,786	$ 1,164,098
Research and development	609,378	22,500
Loss from Operations	(1,028,164)	(1,186,598)
Other Income (Expense)
Changes in fair value of derivative liabilities	46,440	(338,297)
Accretion of discount on convertible notes		(483,636)
Interest and financing charges		(35,269)
Loss on extinguishment of debt		(27,663,430)
Net Loss for the Period	(981,724)	(29,707,230)
Other comprehensive income
Foreign exchange translation adjustment		(1,249)
TOTAl COMPREHENSIVE LOSS	$ (981,724)	$ (29,708,479)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.04)	$ (3.89)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	27,611,255	7,631,669

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited) - 3 months ended Mar. 31, 2015 - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, Shares at Dec. 31, 2014	20,318,816
Balance Amount at Dec. 31, 2014	$ 20,319	$ 85,265,776	$ (86,309,731)	$ (1,023,636)
Private placement (net of finders’ fee of $140,000), Shares	12,319,995
Private placement (net of finders’ fee of $140,000), Amount	$ 12,320	2,313,694		2,326,014
Fair value of warrants recognized as derivative liabilities		(2,090,000)		(2,090,000)
Stock- based compensation		3,750		3,750
Net loss			(981,724)	(981,724)
Balance, Shares at Mar. 31, 2015	32,638,811
Balance Amount at Mar. 31, 2015	$ 32,639	$ 85,493,220	$ (87,291,455)	$ (1,765,596)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) (Parenthetical)	3 Months Ended
	Mar. 31, 2015 USD ($)
Statement of Stockholders' Equity [Abstract]
Finders fee	$ 140,000

Statements of Cash Flows - USD ($)	3 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (981,724)	$ (29,707,230)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(46,440)	338,297
Loss on extinguishment of debt		27,663,430
Non-cash interest and finance charges		483,636
Stock based compensation	3,750	690,000
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	9,961	158,913
NET CASH USED IN OPERATING ACTIVITIES	(1,014,453)	(372,954)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000	2,326,014
Convertible note issuance		418,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,326,014	418,000
INCREASE (DECREASE) IN CASH	1,311,561	45,046
CASH, BEGINNING OF YEAR	141,944	48,589
CASH, END OF YEAR	1,453,505	93,635
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock		513,000
Conversion of debt obligations into common stock:
Accrued interest		476,000
Convertible notes payable		3,293,000
Loans payable, related party		42,000
Promissory notes, related party		210,000
Due to related parties		369,000
Fair value derivative liability – conversion option at conversion		$ 708,000

Statements of Cash Flows (Parenthetical)	3 Months Ended
Statements of Cash Flows (Parenthetical)	Mar. 31, 2015 USD ($)
Statement of Cash Flows [Abstract]
Issuance costs	$ 140,000

NATURE OF OPERATIONS

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1: Nature of Operations

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2: Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

LIQUIDITY AND FINANCIAL CONDITION

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of March 31, 2015, the Company had cash and cash equivalents of approximately $1,454,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015.

Prior Period Reclassifications

Certain prior period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.

POTENTIALLY DILUTIVE SECURITIES

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

POTENTIALLY DILUTIVE SECURITIES

Note 5: pOTENTIALLY DILUTIVE SECURITIES

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three months ended March 31, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:

	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		52,229,000		193,000
Common stock warrants - liability treatment		12,514,000		57,000
Convertible notes		-		15,000
Potentially dilutive securities		64,808,000		330,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION

Note 6: DERIVATIVE LIABILITY - WARRANTs AND DERIVATIVE LIABILITY – CONVERSION OPTION

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended 2015 and 2014 is as follows:

Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	1.52		$	5.84
Volatility (annual)		155.00	%		159.00	%
Risk-free rate		1.37	%		0.65	%
Contractual term (years)		4.85			3.83

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants and Derivative liability – conversion option:

	As of March 31, 2015
		Fair Value Measurements
	Fair Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 2,053,000	-	-	$ 2,053,000	$ 2,053,000
Total	$ 2,053,000	-	-	$ 2,053,000	$ 2,053,000

	As of December 31, 2014
		Fair Value Measurements
	Fair Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 9,000	-	-	$ 9,000	$ 9,000
Total	$ 9,000	-	-	$ 9,000	$ 9,000

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:

	Derivative liability – warrants
Balance – December 31, 2014	$ 9,000
Additions during the quarter	2,090,000
Change in fair value of warrant liability	(46,000)
Balance – March 31, 2015	$ 2,053,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

ring 2014 the Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:

Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		-	%		0	%
Strike price	$	-		$	1.03
Volatility (annual)		-	%		199.00	%
Risk-free rate		-	%		0.05	%
Contractual term (years)		-			0.24

Fair value of Conversion Option at extinguishment	$	-		$	708,000

PROMISSORY NOTE

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

PROMISSORY NOTE

Note 7: Promissory notes, related party

The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

CAPITAL STOCK

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

CAPITAL STOCK

Note 8: Capital Stock

2015 Share Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

The Series A warrants were issued with price reset features. The fair value of these warrants was determined to be $1,346,000 and recognized as a derivative liability.

The fair value of Series B, C, D & E warrants was determined to be $4,635,000 and was included within equity.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

The Series A warrants were issued with price reset features. The fair value of these warrants was determined to be $744,000 and recognized as a derivative liability.

The fair value of Series B, C, D & E warrants was determined to be $2,588,000 and was included within equity.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of March 31, 2015 and changes during the period is presented below:

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life

Balance, December 31, 2014	2,659,417	1.83	4.15
Issued	62,090,975	1.03	3.96
Exercised	-	-	-
Extinguished or expired	(7,500)	50.00	-
Balance, March 31, 2015	64,742,892	$ 1.01	3.95

CONTINGENCIES AND COMMITMENTS

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

CONTINGENCIES AND COMMITMENTS

Note 9: ContingencIES AND COMMITMENTs

Contingencies:

Consultant Litigation

In May 2012, the Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services provided and initially was not able to delay the sale of the contested shares. The Company was not successful in recovering the contested shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting of the issuance of the shares was not has been filed in the Supreme Court of New York. The claim was not for damages on the difference between market price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all of his shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000 that the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the International Arbitration Tribunal held in New York on May 13-16, 2014 the arbitrator ordered (on July 18, 2014) the consultant to pay Tapimmune $196,204 plus 9% interest from the date of the award. The Company is attempting to collect the award from Mr. Michael Gardner.

On July 18, 2014, the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of TapImmune Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently induced into entering said agreement through “1) misrepresentations as to what he would or could do for the Company, including raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune” among other reasons. We are attempting to collect the award from Mr. Gardner.

Vendor Litigation

One of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them and is currently accrued on the balance sheet. We intend on settling that matter in the second quarter of 2015.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Prior Period Reclassifications

Prior Period Reclassifications

POTENTIALLY DILUTIVE SECURITIES (Table)

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

POTENTIALLY DILUTIVE SECURITIES

	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		52,229,000		193,000
Common stock warrants - liability treatment		12,514,000		57,000
Convertible notes		-		15,000
Potentially dilutive securities		64,808,000		330,000

DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

valuation methodology

Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	1.52		$	5.84
Volatility (annual)		155.00	%		159.00	%
Risk-free rate		1.37	%		0.65	%
Contractual term (years)		4.85			3.83

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

	As of March 31, 2015
		Fair Value Measurements
	Fair Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 2,053,000	-	-	$ 2,053,000	$ 2,053,000
Total	$ 2,053,000	-	-	$ 2,053,000	$ 2,053,000

	As of December 31, 2014
		Fair Value Measurements
	Fair Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 9,000	-	-	$ 9,000	$ 9,000
Total	$ 9,000	-	-	$ 9,000	$ 9,000

Measured at fair value

	Derivative liability – warrants
Balance – December 31, 2014	$ 9,000
Additions during the quarter	2,090,000
Change in fair value of warrant liability	(46,000)
Balance – March 31, 2015	$ 2,053,000

Numerous extinguishment agreements

Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		-	%		0	%
Strike price	$	-		$	1.03
Volatility (annual)		-	%		199.00	%
Risk-free rate		-	%		0.05	%
Contractual term (years)		-			0.24

Fair value of Conversion Option at extinguishment	$	-		$	708,000

CAPITAL STOCK (Tables)

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

Share purchase warrants

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life

Balance, December 31, 2014	2,659,417	1.83	4.15
Issued	62,090,975	1.03	3.96
Exercised	-	-	-
Extinguished or expired	(7,500)	50.00	-
Balance, March 31, 2015	64,742,892	$ 1.01	3.95

LIQUIDITY AND FINANCIAL CONDITION (Details Narrtive)	Mar. 31, 2015 USD ($)
Liquidity And Financial Condition Details Narrtive
Cash and cash equivalents	$ 1,454,000

POTENTIALLY DILUTIVE SECURITIES (Details) - shares	3 Months Ended
POTENTIALLY DILUTIVE SECURITIES (Details) - shares	Mar. 31, 2015	Mar. 31, 2014
Potentially Dilutive Securities Details
Common stock options	65,000	65,000
Common stock warrants - equity treatment	52,229,000	193,000
Common stock warrants - liability treatment	12,514,000	57,000
Convertible notes		15,000
Potentially dilutive securities	64,808,000	330,000

PROMISSORY NOTES, RELATED PARTY (Details Narrative)	Dec. 31, 2014 USD ($)
Outstanding promissory notes in the amount	$ 52,942
Officer Director [Member]
Outstanding promissory notes in the amount	$ 23,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Details ) - $ / shares	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Strike price		$ 1.03
Share Purchase Warrants[Member]
Contractual Life (Years)	4 years 10 months 6 days	3 years 9 months 29 days
Risk free Rate	1.37%	0.65%
Dividend yield	0.00%	0.00%
Volatility	155.00%	159.00%
Strike price	$ 1.52	$ 5.84

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Details 1) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Derivative liability - warrants	$ 9,000	$ 2,053,000
Total	9,000	2,053,000
Fair Value [Member]
Derivative liability - warrants		2,053,000
Total		2,053,000
Fair Value, Inputs, Level 1 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability - warrants	9,000	2,053,000
Total	9,000	$ 2,053,000
Carrying Value [Member]
Derivative liability - warrants	9,000
Total	$ 9,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION (Details 2)	3 Months Ended
	Mar. 31, 2015 USD ($)
Notes to Financial Statements
Balance - December 31, 2013	$ 9,000
Additions during the quarter	2,090,000
Change in fair value of warrant liability	(46,000)
Balance - December 31, 2014	$ 2,053,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION (Details 3) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Notes to Financial Statements
Dividend yield (per share)		0.00%
Strike price		$ 1.03
Volatility (annual)		199.00%
Risk-free rate		0.05%
Contractual term (years)		2 months 27 days
Fair value of Conversion Option at extinguishment		$ 708,000

CAPITAL STOCK (Details)	3 Months Ended
CAPITAL STOCK (Details)	Mar. 31, 2015 $ / shares shares
Number of Warrants
Issued \| shares	62,090,975
Exercised \| shares
Extinguished or expired \| shares	(7,500)
Balance, March 31, 2015 \| shares	64,742,892
Weighted Average Exercise Price
Issued \| $ / shares	$ 1.03
Exercised \| $ / shares
Extinguished or expired \| $ / shares	50.00
Balance, March 31, 2015 \| $ / shares	$ 1.01
Weighted Average Remaining Life
Balance, December 31, 2014	4 years 1 month 24 days
Issued	3 years 11 months 16 days
Balance, March 31, 2015	3 years 11 months 12 days

CONTINGENCIES AND COMMITMENTS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Number of post-consolidated shares of common stock	112,000
Claim for alleged damages	$ 362,000
Bond payment	100,000
Amount paid by consultant	$ 196,204
Interest paid by consultant	9.00%
Unpaid legal fees	$ 210,255
Award amount		$ 196,204
Judgment award amount	$ 51,000

Label	Element	Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 1.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2,659,417